News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epigenomics AG Issues Convertible Bonds



9/8/2017 8:35:21 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Berlin (Germany) and Germantown, MD (U.S.A.), September 8, 2017 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the "Company", today announced that it has issued convertible bonds with a nominal value of EUR 7.1 million to Cathay Fortune International Company Limited (CFIC) excluding pre-emptive rights of existing shareholders. The issuance of the convertible bonds, as agreed in the Business Combination Agreement on April 26, 2017 between Epigenomics and CFIC and published in the offer document for the voluntary public takeover offer on June 8, 2017, provides an immediate cash inflow of approximately EUR 6.5 million to the Company.

The bonds were issued at 91% of their nominal amount, carry no interest, have a term until December 31, 2018 and are convertible into up to 994,397 shares of Epigenomics.

Further details regarding terms and conditions in connection with the issuance of convertible bonds according to the agreement with CFIC were provided in the offer document for the voluntary public takeover offer on June 8, 2017.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.

For more information, visit www.epigenomics.com.

Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES